Market cap
$9.4bn
Earnings yield vs 10-yr compares what the business earns per pound invested against the 5.28% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.
Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.
Commercial Products Our commercial products are our primary sources of revenue and are expected to be key contributors to future revenue growth. Subsequent to our IPO, we financed our operations primarily through proceeds from sales of our common stock to equity investors and debt borrowings. We are eligible to receive sales-based and other milestone payments totaling up to €94.5 million. The royalty payments due to Jazz are a high single-digit royalty on our U.S. net sales of SUNOSI in the current indication and a mid single-digit royalty on our U.S. net sales of SUNOSI for future indications. AUVELITY U.S. …Axsome Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-10